Taysha Gene Therapies Inc
For the period ended Sep 30, 2024. Filed Nov 13, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 13, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Statements of Stockholders’ (Deficit) Equity
Condensed Consolidated Statements of Stockholders’ (Deficit) Equity
(in thousands, except share data)
For the Three Months Ended September 30, 2024
| Additional · Accumulated · Total | ||||||
|---|---|---|---|---|---|---|
| Common Stock · Paid-in · Accumulated · Other · Stockholders' | ||||||
| Shares | Amount | Capital | Deficit | Comprehensive Loss | Deficit | |
| Balance as of June 30, 2024 | 201,381,450 | $2 | $664,457 | $(557,996) | $2,405 | $108,868 |
| Stock-based compensation | — | — | 3,357 | — | — | 3,357 |
| Issuance of common stock and pre-funded warrants upon closing of underwritten public offering, net of underwriting discounts and commissions, and other offering costs of $542 | 3,235,000 | — | 6,737 | — | — | 6,737 |
| Issuance of common stock under ESPP | 47,170 | — | 63 | — | — | 63 |
| Issuance of common stock upon exercise of stock options, net | 56,770 | — | 38 | — | — | 38 |
| Issuance of common stock upon vesting and settlement of restricted stock units, net | 222,916 | — | (9) | — | — | (9) |
| Loss on instrument-specific credit risk | — | — | — | — | (4,733) | (4,733) |
| Net loss | — | — | — | (25,524) | — | (25,524) |
| Balance as of September 30, 2024 | 204,943,306 | $2 | $674,643 | $(583,520) | $(2,328) | $88,797 |
For the Three Months Ended September 30, 2023
| Additional · Accumulated · Total | ||||||
|---|---|---|---|---|---|---|
| Common Stock · Paid-in · Accumulated · Other · Stockholders' | ||||||
| Shares | Amount | Capital | Deficit | Comprehensive Loss | Equity | |
| Balance as of June 30, 2023 | 64,432,637 | $1 | $406,546 | $(443,661) | $— | $(37,114) |
| Stock-based compensation | — | — | 2,040 | — | — | 2,040 |
| Issuance of common stock in private placement, net of placement agent commission and offering costs of $7,098 | 122,412,376 | 1 | 103,028 | — | — | 103,029 |
| Issuance of common stock upon vesting and settlement of restricted stock units | 82,780 | — | — | — | — | — |
| Issuance of common stock under ESPP | 32,400 | — | 18 | — | — | 18 |
| Net loss | — | — | — | (117,087) | — | (117,087) |
| Balance as of September 30, 2023 | 186,960,193 | $2 | $511,632 | $(560,748) | $— | $(49,114) |
Condensed Consolidated Statements of Stockholders’ (Deficit) Equity
(in thousands, except share data)
For the Nine Months Ended September 30, 2024
| Additional | ||||||
|---|---|---|---|---|---|---|
| Common Stock · Paid-in · Accumulated · Accumulated Other · Total | ||||||
| Shares | Amount | Capital | Deficit | Comprehensive Loss | Stockholders' Equity | |
| Balance as of December 31, 2023 | 186,960,193 | $2 | $587,942 | $(513,007) | $— | $74,937 |
| Stock-based compensation | — | — | 9,887 | — | — | 9,887 |
| Issuance of common stock and pre-funded warrants upon closing of underwritten public offering, net of underwriting discounts and commissions, and other offering costs of $5,566 | 17,596,113 | — | 76,694 | — | — | 76,694 |
| Issuance of common stock upon vesting and settlement of restricted stock units | 234,198 | — | (9) | — | — | (9) |
| Issuance of common stock under ESPP | 93,970 | — | 89 | — | — | 89 |
| Issuance of common stock upon exercise of stock options | 58,832 | — | 40 | — | — | 40 |
| Loss on instrument-specific credit risk | — | — | — | — | (2,328) | (2,328) |
| Net loss | — | — | — | (70,513) | — | (70,513) |
| Balance as of September 30, 2024 | 204,943,306 | $2 | $674,643 | $(583,520) | $(2,328) | $88,797 |
For the Nine Months Ended September 30, 2023
| Additional · Total | ||||||
|---|---|---|---|---|---|---|
| Common Stock · Paid-in · Accumulated · Accumulated Other · Stockholders' | ||||||
| Shares | Amount | Capital | Deficit | Comprehensive Loss | Equity (Deficit) | |
| Balance as of December 31, 2022 | 63,207,507 | $1 | $402,389 | $(401,441) | $— | $949 |
| Stock-based compensation | — | — | 5,937 | — | — | 5,937 |
| Issuance of common stock in private placement, net of placement agent commission and offering costs of $7,138 | 123,117,594 | 1 | 103,238 | — | — | 103,239 |
| Issuance of common stock upon vesting and settlement of restricted stock units, net | 566,772 | — | — | — | — | — |
| Issuance of common stock under ESPP | 68,320 | — | 68 | — | — | 68 |
| Net loss | — | — | — | (159,307) | — | (159,307) |
| Balance as of September 30, 2023 | 186,960,193 | $2 | $511,632 | $(560,748) | $— | $(49,114) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.